Literature DB >> 32156035

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives.

Fulvio Borella1, Eleonora Ghisoni2,3, Gaia Giannone2,3, Stefano Cosma1, Chiara Benedetto1, Giorgio Valabrega2,3, Dionyssios Katsaros1.   

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological cancers. Despite improvements in medical treatments, the prognosis for EOC remains poor, and there is an urgent need for new therapeutic strategies. Immune checkpoint inhibitors (CPIs) have dramatically improved survival of several cancers and are under evaluation in OC. Unfortunately, CPIs have shown globally unsatisfactory results. The aim of this manuscript is to critically review the results from early-phase trials with CPIs in terms of safety and activity, discuss the possible reasons for disappointing results and the new therapeutic approaches to improve patient outcomes.

Entities:  

Keywords:  Ovarian cancer; biomarkers; clinical trials; immune checkpoint inhibitors; immunotherapy; safety

Year:  2020        PMID： 32156035     DOI： 10.3390/diagnostics10030146

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN： 2075-4418


  21 in total

1.  Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer.

Authors:  Kalika Kamat; Venkatesh Krishnan; Oliver Dorigo
Journal:  Br J Cancer       Date:  2022-06-24       Impact factor: 9.075

Review 2.  Cabozantinib for the treatment of solid tumors: a systematic review.

Authors:  Pablo Maroto; Camillo Porta; Jaume Capdevila; Andrea B Apolo; Santiago Viteri; Cristina Rodriguez-Antona; Lidia Martin; Daniel Castellano
Journal:  Ther Adv Med Oncol       Date:  2022-07-13       Impact factor: 5.485

Review 3.  Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.

Authors:  Gabriel Osborn; Chara Stavraka; Rebecca Adams; Ahmad Sayasneh; Sharmistha Ghosh; Ana Montes; Katie E Lacy; Rebecca Kristeleit; James Spicer; Debra H Josephs; James N Arnold; Sophia N Karagiannis
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

4.  The Spatial Context of Tumor-Infiltrating Immune Cells Associates with Improved Ovarian Cancer Survival.

Authors:  Benjamin Steinhart; Kimberly R Jordan; Jaidev Bapat; Miriam D Post; Lindsay W Brubaker; Benjamin G Bitler; Julia Wrobel
Journal:  Mol Cancer Res       Date:  2021-10-06       Impact factor: 6.333

Review 5.  Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.

Authors:  Fulvio Borella; Mario Preti; Luca Bertero; Giammarco Collemi; Isabella Castellano; Paola Cassoni; Stefano Cosma; Andrea Roberto Carosso; Federica Bevilacqua; Niccolò Gallio; Chiara Benedetto; Leonardo Micheletti
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

Review 6.  Cell therapies in ovarian cancer.

Authors:  Apostolos Sarivalasis; Matteo Morotti; Arthur Mulvey; Martina Imbimbo; George Coukos
Journal:  Ther Adv Med Oncol       Date:  2021-04-22       Impact factor: 8.168

7.  Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response.

Authors:  Elise K Mann; Kevin J Lee; Dongquan Chen; Luciana Madeira da Silva; Valeria L Dal Zotto; Jennifer Scalici; Natalie R Gassman
Journal:  Biology (Basel)       Date:  2021-04-29

Review 8.  Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

Authors:  Alia Ghoneum; Sameh Almousa; Bailey Warren; Ammar Yasser Abdulfattah; Junjun Shu; Hebatullah Abouelfadl; Daniela Gonzalez; Christopher Livingston; Neveen Said
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 15.707

9.  Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients.

Authors:  S T Paijens; A Vledder; D Loiero; E W Duiker; J Bart; A M Hendriks; M Jalving; H H Workel; H Hollema; N Werner; A Plat; G B A Wisman; R Yigit; H Arts; A J Kruse; N M de Lange; V H Koelzer; M de Bruyn; H W Nijman
Journal:  Oncoimmunology       Date:  2021-06-06       Impact factor: 8.110

10.  Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.

Authors:  Alyssa A Hoover; Demetra H Hufnagel; Whitney Harris; Kennady Bullock; Evan B Glass; Esther Liu; Whitney Barham; Marta A Crispens; Dineo Khabele; Todd D Giorgio; Andrew J Wilson; Fiona E Yull
Journal:  BMC Cancer       Date:  2020-10-07       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.